6.71
0.06 (0.90%)
| Previous Close | 6.65 |
| Open | 6.50 |
| Volume | 309,690 |
| Avg. Volume (3M) | 1,066,226 |
| Market Cap | 5,599,240,192 |
| Price / Earnings (TTM) | 26.84 |
| Price / Earnings (Forward) | 10.91 |
| Price / Sales | 0.580 |
| Price / Book | 0.710 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2025 - 16 May 2025 |
| Profit Margin | 2.18% |
| Operating Margin (TTM) | 21.43% |
| Diluted EPS (TTM) | 0.250 |
| Quarterly Revenue Growth (YOY) | 11.70% |
| Quarterly Earnings Growth (YOY) | 76.90% |
| Total Debt/Equity (MRQ) | 117.53% |
| Current Ratio (MRQ) | 2.66 |
| Operating Cash Flow (TTM) | 902.17 M |
| Levered Free Cash Flow (TTM) | 1.45 B |
| Return on Assets (TTM) | 3.89% |
| Return on Equity (TTM) | 2.64% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - General (US) | Mixed | Bullish |
| Drug Manufacturers - General (Global) | Mixed | Bullish | |
| Stock | Grifols, S.A. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -0.67 |
|
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Investment Style | Mid Growth |
| % Held by Institutions | 56.13% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Permian Investment Partners, Lp | 31 Dec 2024 | 16,187,321 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 14 Jan 2025 | Announcement | Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson’s Disease |
| 13 Jan 2025 | Announcement | Mason Capital Management Sends Letter to Spanish National Securities Market Commission Regarding Lack of Transparency by Grifols |
| 5Y Average Dividend Yield | 1.03% |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 03 Jun 2021 | 21 May 2021 | 14 Jun 2021 | 0.456586 Cash |
| 30 Oct 2020 | 16 Oct 2020 | 09 Nov 2020 | 0.201439 Cash |
| 02 Dec 2019 | 31 Oct 2019 | 11 Dec 2019 | 0.221872 Cash |
| 07 Jun 2019 | 29 May 2019 | 18 Jun 2019 | 0.175638 Cash |
| 30 Nov 2018 | 07 Nov 2018 | 11 Dec 2018 | 0.22789 Cash |
| 01 Jun 2018 | 25 May 2018 | 12 Jun 2018 | 0.250975 Cash |
| 01 Dec 2017 | - | 12 Dec 2017 | 0.212979 Cash |
| 30 May 2017 | - | 08 Jun 2017 | 0.163528 Cash |
| 05 Dec 2016 | - | 14 Dec 2016 | 0.193644 Cash |
| 02 Jun 2016 | - | 15 Jun 2016 | 0.162059 Cash |
| 10 Dec 2015 | - | 17 Dec 2015 | 0.384765 Cash |
| 08 Jun 2015 | - | 15 Jun 2015 | 0.341846 Cash |
| 04 Dec 2014 | - | 12 Dec 2014 | 0.312792 Cash |
| 05 Jun 2013 | 24 May 2013 | 13 Jun 2013 | 0.258668 Cash |
| Show more | |||
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2021 | 0.457 | 1 | 4.07 |
| 2020 | 0.201 | 1 | 1.09 |
| 2019 | 0.398 | 2 | 1.71 |
| 2018 | 0.479 | 2 | 2.61 |
| 2017 | 0.377 | 2 | 1.64 |
| 2016 | 0.356 | 2 | 2.21 |
| 2015 | 0.727 | 2 | 4.49 |
| 2014 | 0.313 | 1 | 1.84 |
| 2013 | 0.259 | 1 | 1.43 |
| Show more | |||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |